ANN ARBOR, MI – Esperion announced Wednesday it has completed its acquisition of Corstasis Therapeutics Inc., gaining the first FDA-approved nasal spray loop diuretic as it expands its cardiovascular treatment portfolio.
The Ann Arbor-based biopharmaceutical company acquired the privately held Corstasis, developer of Enbumyst, which received FDA approval in September 2025 for treating edema associated with congestive heart failure, as well as hepatic and renal disease in adults.
“The closing of this acquisition…strengthens our commitment to delivering differentiated therapies that address the growing global burden of cardiometabolic disease,” said Sheldon Koenig, president and chief executive officer of Esperion. “Enbumyst is a novel, patient-friendly option that we believe can meaningfully improve fluid management for congestive heart failure patients.”…